A Phase 3 interventional study of QM1114-DP and Placebo in Glabellar Frown Lines, sponsored by Galderma R&D. Completed at 9 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-21.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the aesthetic improvement and onset of QM1114-DP treatment for subjects with moderate to severe glabellar lines
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
a Botulinum Toxin Type A (BoNT-A)
Biological: QM1114-DP
Biological: Placebo
QM1114-DP
Placebo
Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1
Participant assessment at Month 1 of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale. GAIS is a 7-graded scale: Very much worse; much worse; worse; no change; improved; much improved; or very much improved. A responder was defined as a participant who responded "improved," "much improved," or "very much improved" on the participant GAIS at maximum frown. Missing data is imputed as no change (non-responder).
Time frame: At Month 1
Percentage of Participants Reporting Onset of Treatment Effect Using the Diary Card
Following treatment at baseline, participants were asked to record their assessment of study treatment response in a diary card on Days 0 through 7. They were asked to respond "yes" or "no" to the following question: "Since being injected, have you noticed an improvement in the appearance of your glabellar lines (lines between your eyebrows) when you frown?" Response to treatment effect given by a Participant on first day as "yes" to the diary question.
Time frame: At Days 0 through 7 post-treatment
Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) From Day 1 Through Month 12
Participant assessment From Day 1 through Month 12 of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale. GAIS is a 7-graded scale: Very much worse; much worse; worse; no change; improved; much improved; or very much improved. A responder was defined as a Participant who responded "improved," "much improved," or "very much improved" on the GAIS at maximum frown. This analysis is based on observed cases.
Time frame: From Day 1 through Month 12
This study was conducted at 9 investigational centers in the United States (US) from 09 May 2022 to 01 September 2023.
| Milestone | Experimental: QM1114-DP | Placebo Comparator: Placebo |
|---|---|---|
| Started | 99 | 33 |
| Completed | 89 | 27 |
| Not completed | 10 | 6 |
| Withdrew: Withdrew consent | 6 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Other | 1 | 3 |
Participant assessment at Month 1 of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale. GAIS is a 7-graded scale: Very much worse; much worse; worse; no change; improved; much improved; or very much improved. A responder was defined as a participant who responded "improved," "much improved," or "very much improved" on the participant GAIS at maximum frown. Missing data is imputed as no change (non-responder).
| Participants | Experimental: QM1114-DP | Placebo Comparator: Placebo |
|---|---|---|
| Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1 | 92 | 3 |
Following treatment at baseline, participants were asked to record their assessment of study treatment response in a diary card on Days 0 through 7. They were asked to respond "yes" or "no" to the following question: "Since being injected, have you noticed an improvement in the appearance of your glabellar lines (lines between your eyebrows) when you frown?" Response to treatment effect given by a Participant on first day as "yes" to the diary question.
| Participants | Experimental: QM1114-DP | Placebo Comparator: Placebo |
|---|---|---|
| Percentage of Participants Reporting Onset of Treatment Effect Using the Diary Card | 89 | 3 |
Participant assessment From Day 1 through Month 12 of aesthetic change from baseline of the treated areas using the Global Aesthetic Improvement Scale. GAIS is a 7-graded scale: Very much worse; much worse; worse; no change; improved; much improved; or very much improved. A responder was defined as a Participant who responded "improved," "much improved," or "very much improved" on the GAIS at maximum frown. This analysis is based on observed cases.
| participants | Experimental: QM1114-DP | Placebo Comparator: Placebo |
|---|---|---|
| Day 1 | 39 (30.10 to 49.49) | 4 (0.99 to 23.26) |
| Day 2 | 66 (58.06 to 76.63) | 4 (1.04 to 23.96) |
| Day 3 | 79 (73.71 to 89.18) | 4 (1.10 to 24.70) |
| Day 4 | 87 (84.79 to 96.46) | 4 (1.10 to 24.70) |
| Month 1 | 92 (89.13 to 98.62) | 3 (0.00 to 20.08) |
| Month 3 | 87 (82.53 to 95.03) | 1 (0.00 to 9.76) |
| Month 6 | 64 (58.66 to 77.51) | 1 (0.00 to 9.76) |
| Month 7 | 51 (45.85 to 66.24) | 1 (0.00 to 10.09) |
| Month 8 | 45 (39.18 to 59.72) | 1 (0.00 to 10.83) |
| Month 9 | 38 (32.42 to 52.97) | 1 (0.00 to 10.83) |
| Month 10 | 32 (26.99 to 47.43) | 0 (0.00 to 0.00) |
| Month 11 | 31 (25.90 to 46.19) | 0 (0.00 to 0.00) |
| Month 12 | 34 (27.76 to 47.79) | 1 (0.00 to 10.09) |
Collected over From Day 1 up to end of study (Up to 12 Months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: QM1114-DP | 0/99 (0%) | 0/99 (0%) | 39/99 (39.4%) |
| Placebo Comparator: Placebo | 0/33 (0%) | 0/33 (0%) | 7/33 (21.2%) |
| Event | Experimental: QM1114-DP | Placebo Comparator: Placebo |
|---|---|---|
| COVID-19Infections and infestations | 7/99 | 3/33 |
| Upper respiratory tract infectionInfections and infestations | 4/99 | 2/33 |
| HeadacheNervous system disorders | 6/99 | 0/33 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/99 | 0/33 |
| SinusitisInfections and infestations | 3/99 | 0/33 |
| Procedural painInjury, poisoning and procedural complications | 3/99 | 0/33 |
| HordeolumInfections and infestations | 1/99 | 1/33 |
| InfluenzaInfections and infestations | 1/99 | 1/33 |
| GastroenteritisInfections and infestations | 0/99 | 1/33 |
| MigraineNervous system disorders | 0/99 | 1/33 |
Intent to treat (ITT) population included all participants who were randomized and analyzed according to the treatment they were randomized based on the randomization scheme.
| Age, Continuous(years) | Experimental: QM1114-DP | Placebo Comparator: Placebo | Total |
|---|---|---|---|
| Mean | 52.1 ± 10.72 | 52.5 ± 10.31 | 52.2 ± 10.58 |
| Sex: Female, Male(Participants) | Experimental: QM1114-DP | Placebo Comparator: Placebo | Total |
|---|---|---|---|
| Female | 94 | 31 | 125 |
| Male | 5 | 2 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: QM1114-DP | Placebo Comparator: Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 34 | 13 | 47 |
| Not Hispanic or Latino | 65 | 20 | 85 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Experimental: QM1114-DP | Placebo Comparator: Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 0 | 1 | 1 |
| White | 92 | 31 | 123 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in Oct 2022, 5 months.
Results were first posted in Oct 2024, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A